Skip to main content
. 2020 Feb 26;34(3):395–404. doi: 10.1007/s40259-020-00409-y
The indication for use of infliximab-dyyb in inflammatory bowel disease (IBD) was approved based on extrapolation of data from reference product (RP) infliximab by the US Food and Drug Administration.
This study evaluated the outcomes of patients with IBD who switched from RP infliximab to the biosimilar, infliximab-dyyb.
Comparing patients in the infliximab-dyyb group to a matched group of patients with IBD who remained on RP infliximab, the study demonstrated that infliximab-dyyb was non-inferior to RP infliximab in a real-world setting in the United States.
The biosimilar infliximab-dyyb is another treatment option for patients with IBD as it has similar effectiveness to RP infliximab.